Acrivon Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 12, 2026
ACRV$1.57-0.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share data)
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Operating expenses: | ||||
| Research and development | $13,844 | $16,182 | $29,010 | $31,596 |
| General and administrative | 4,824 | 6,467 | 9,560 | 12,715 |
| Total operating expenses | 18,668 | 22,649 | 38,570 | 44,311 |
| Loss from operations | (18,668) | (22,649) | (38,570) | (44,311) |
| Other income (expense), net: | ||||
| Interest income | 860 | 1,730 | 1,849 | 3,726 |
| Other expense, net | (156) | (87) | (285) | (101) |
| Total other income, net | 704 | 1,643 | 1,564 | 3,625 |
| Net loss | $(17,964) | $(21,006) | $(37,006) | $(40,686) |
| Net loss per share—basic and diluted | $(0.43) | $(0.55) | $(0.92) | $(1.06) |
| Weighted-average common stock outstanding—basic and diluted | 41,841,887 | 38,461,619 | 40,291,956 | 38,406,339 |
| Comprehensive loss: | ||||
| Net loss | $(17,964) | $(21,006) | $(37,006) | $(40,686) |
| Other comprehensive loss: | ||||
| Unrealized loss on available-for-sale investments, net of tax | (37) | (177) | (144) | (341) |
| Comprehensive loss | $(18,001) | $(21,183) | $(37,150) | $(41,027) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.